Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics

Adaptimmune Therapeutics plc (ADAP): $0.89

0.02 (+1.97%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ADAP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#151 of 347

in industry

ADAP Price/Volume Stats

Current price $0.89 52-week high $2.05
Prev. close $0.87 52-week low $0.42
Day low $0.86 Volume 588,900
Day high $0.90 Avg. volume 1,711,310
50-day MA $1.07 Dividend yield N/A
200-day MA $0.94 Market Cap 219.67M

ADAP Stock Price Chart Interactive Chart >


Adaptimmune Therapeutics plc (ADAP) Company Bio


Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.


ADAP Latest News Stream


Event/Time News Detail
Loading, please wait...

ADAP Latest Social Stream


Loading social stream, please wait...

View Full ADAP Social Stream

Latest ADAP News From Around the Web

Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.

Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year

Key Insights Institutions' substantial holdings in Adaptimmune Therapeutics implies that they have significant...

Yahoo | December 7, 2023

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacyPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission o

Yahoo | December 6, 2023

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Yahoo | November 30, 2023

Adaptimmune Receives Transfer of IND for Lete-cel Program

Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel

Yahoo | November 29, 2023

Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 13, 2023

Read More 'ADAP' Stories Here

ADAP Price Returns

1-mo -15.24%
3-mo -38.19%
6-mo 78.00%
1-year -10.10%
3-year -76.94%
5-year -75.68%
YTD 12.23%
2023 -45.68%
2022 -61.07%
2021 -30.43%
2020 349.17%
2019 -79.13%

Continue Researching ADAP

Here are a few links from around the web to help you further your research on Adaptimmune Therapeutics PLC's stock as an investment opportunity:

Adaptimmune Therapeutics PLC (ADAP) Stock Price | Nasdaq
Adaptimmune Therapeutics PLC (ADAP) Stock Quote, History and News - Yahoo Finance
Adaptimmune Therapeutics PLC (ADAP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!